The Dow Laboratory investigates tumor immune responses and develops new cancer immunotherapies. The laboratory also develops immunotherapies to prevent respiratory tract infections in cattle, dogs and cats, as well as for treatment of ocular viral infections and ocular cancer in horses and cats. A third program focuses on stem cell therapy for treatment of chronic infections and for wound healing, with studies in rodent models and pet dogs.
research project
Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma
Despite a multitude of clinical trials geared to eliminating tumor spread, approximately 30% of people with osteosarcoma (OS) still die of disease. We will use dogs with spontaneous OS to test a series of promising novel immune therapies and leverage this data to create a blueprint for future human trials.
view project
research project
Development of new combination immunotherapy/vaccination approaches for treatment of brain cancer and bone cancer in dogs and humans
This program is developing new tumor vaccine and immunotherapy approaches to treat both metastatic bone cancer and brain cancer, using mouse models and clinical trials in pet dogs at the Flint Animal Cancer Center. These studies are also intended to help accelerate the development of new treatments for human cancer, working with colleagues at Children’s Hospital and the Anschutz Medical Campus.
research project
Cellular therapy with mesenchymal stromal cells for treatment of chronic drug resistant infections in dogs and humans
The laboratory is pioneering the use of activated cellular therapy (ACT) to treat highly drug-resistant bacterial infections in companion animals and humans. The studies in mice and pet dogs have demonstrated high activity against common bacterial pathogens, even in the biofilm state, with very low to minimal toxicity.
research project
Development of new checkpoint molecule targeted immunotherapies for cancer immunotherapy in dogs
Checkpoint molecule targeted biologics have transformed human cancer therapies, and this program seeks to develop similar drugs for treatment of cancer in dogs, focusing on co-stimulatory checkpoint molecules such as OX40 and CD40.
research project
Inhalational and ocular immunotherapy for prevention and treatment of viral and bacterial infections in dogs, cats, horses, and cattle
This program is developing new immunotherapies to reduce or eliminate the use of antibiotics to prevent common viral and bacterial infections of both agricultural and companion animals. In addition, a new type of ocular immunotherapy is being developed to be applied as eye drops to treat common viral and neoplastic diseases of the eye in cats and horses and humans.
Publications
Regan DP, Coy JW, Chahal KK, Chow L, Kurihara JN, Guth AM, Kufareva I, Dow SW.
J Immunol. 2019 May 15;202(10):3087-3102. doi: 10.4049/jimmunol.1800619. Epub 2019 Apr 10.
Wheat W, Chow L, Coy J, Contreras E, Lappin M, Dow S.
J Vet Intern Med. 2019 Mar;33(2):838-845. doi: 10.1111/jvim.15426. Epub 2019 Feb 15.
Hartley GP, Chow L, Ammons DT, Wheat WH, Dow SW.
Cancer Immunol Res. 2018 Oct;6(10):1260-1273. doi: 10.1158/2326-6066.CIR-17-0537. Epub 2018 Jul 16.
Johnson V, Webb T, Norman A, Coy J, Kurihara J, Regan D, Dow S.
Sci Rep. 2017 Aug 29;7(1):9575. doi: 10.1038/s41598-017-08311-4.
Soontararak S, Chow L, Johnson V, Coy J, Wheat W, Regan D, Dow S.
Stem Cells Transl Med. 2018 Jun;7(6):456-467. doi: 10.1002/sctm.17-0305. Epub 2018 Apr 10
more publications
Lab rafting trip down the Poudre river.
Dow lab on their rafting trip before getting on the water.
Dow lab on a hiking trip.
contact information
Offices:
Animal Cancer Center room B250
Translational Medicine Institute room 235
Laboratories:
Animal Cancer Center rooms B254, B260
Translational Medicine Institute rooms 235, 250
(970) 297-4014
Steven.Dow@colostate.edu
